Murraya koenigii methanolic extract inhibits bacterial growth and biofilm of Staphylococcus aureus and Enterococcus faecalis.

Hospital-acquired infections caused by Staphylococcus aureus and Enterococcus faecalis are significant global health challenges due to their biofilm-forming ability, also contributing to the derived antibiotic resistance and environmental persistence. This growing resistance poses serious global health challenges, emphasizing the need for better surveillance and new treatments. Plant-derived bioactives have emerged as possible therapeutics to such opportunistic pathogens and they are potential alternatives to traditional antimicrobials. This study investigates the in vitro activity of Murraya koenigii's methanolic (MKM) leaf extract and its compounds against the growth and biofilm-forming ability of S. aureus and E. faecalis. Results revealed that the MKM extract effectively inhibited the growth of S. aureus and E. faecalis at their respective MIC levels. Furthermore, flow cytometry and confocal imaging demonstrated substantial membrane damage in MKM-treated cells compared to DMSO-treated and untreated controls. Additionally, the MKM extract significantly disrupts biofilm formation and leads to reduced extracellular polymeric substance (EPS) production. Scanning electron microscopy provided visual evidence of disrupted biofilm architecture following MKM extract treatment. HR-LC/MS analysis identified bioactive compounds within the extract, which were further evaluated for drug-likeness properties through ADME analysis. In silico molecular docking studies confirmed strong binding affinities of MKM-derived compounds with key biofilm-related receptor proteins, SpA in S. aureus and Esp in E. faecalis. These findings highlight the significant potential of MKM extract as a novel and effective phytotherapeutic resource for developing strategies to combat biofilm-associated infections.